Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Find beginner-friendly options with understandable use cases and liquidity, plus a simple framework to compare potential investments.
27,615 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Alibaba is reshaping itself from a pure e-commerce giant into a cloud and AI contender. With profits under pressure a...
As the 2026 earnings season unfolds, investors want real, actionable insights on fidus (FDUS) 2026 earnings. This ana...
Oil markets face renewed Hormuz-related risk as traders debate a potential NACHO scenario. Could trump nacho trade re...
Investors eye a $100,000 ultra-high-yield portfolio as rates pause and markets prize cash flow. The model promises ro...
Anthropic's Mythos stirred AI headlines and sent one cybersecurity stock soaring. This article breaks down whether PA...
Oracle's backlog surge and accelerating AI infrastructure growth are fueling a heated debate on whether the stock is ...
Private credit keeps making headlines as investors chase higher yields. This guide breaks down dividend safety, risk ...
A single company’s three engines—cloud, ads, and chips—are powering a persistent multi‑billion revenue trajectory, ev...
Retail traders on Robinhood are flocking to a high-yield FANG income ETF, chasing monthly payouts even as upside is c...
Apple advances a leadership shift, naming hardware chief John Ternus as the next CEO, effective Sept. 1, 2026. Tim Co...
A practical, investor-focused look at Kestra Medical's (KMTS) 2026 earnings trajectory. We unpack expected revenue dr...